Balaxi Pharmaceuticals Limited has filed its monthly RTA report with the National Stock Exchange of India Limited for the period ended April 2026, in accordance with SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated 30th January, 2026. The report pertains to the re-lodgement of transfer requests for physical shares under the special window established by the said SEBI circular. The filing was submitted on 12th May, 2026, and signed by Aman Purohit, Company Secretary and Compliance Officer (ICSI Membership No.: A59345).

RTA Report: Physical Share Transfer Re-Lodgements

The report was prepared and submitted by M/s. Aarthi Consultants Private Limited, the Registrar and Share Transfer Agent of Balaxi Pharmaceuticals, bearing SEBI Registration No. INR000000379. Aarthi Consultants, a Category I Registrar and Share Transfer Agent, confirmed the status of re-lodgement requests as of April 2026. The report reflects activity — or the absence thereof — under the special window provided by the SEBI circular dated 30th January, 2026, which governs the re-lodgement of physical share transfer requests.

April 2026 Re-Lodgement Status

The following table summarises the status of physical share transfer re-lodgement requests for the month of April 2026, as reported by Aarthi Consultants Private Limited:

As confirmed by the RTA, no requests for re-lodgement of physical share transfers were received, processed, approved, or rejected during April 2026. Consequently, the average processing time is reported as not applicable for the period.

Regulatory Compliance and Disclosure

The report has been submitted to the Listing Department of the National Stock Exchange of India Limited in compliance with the applicable SEBI circular. Balaxi Pharmaceuticals has also indicated that the report will be made available on the company's official website at www.balaxipharma.in . The filing was made on behalf of Balaxi Pharmaceuticals by Aman Purohit, Company Secretary and Compliance Officer, and the RTA report was signed by Jagan Mohan Gobburi, Compliance Officer at Aarthi Consultants Private Limited, dated 11th May, 2026.

Stock Surge Following Significant Ownership Changes

Balaxi Pharmaceuticals , a prominent player in the pharmaceutical sector, has witnessed a significant surge in its stock price, climbing over 22% in just two days. This remarkable uptick comes on the heels of substantial bulk deals that have reshaped the company's ownership structure.

Bulk Deals Drive Stock Rally

The stock's impressive rally was triggered by a series of high-profile transactions involving major institutional investors. Two funds have each acquired approximately 8% stake in Balaxi Pharmaceuticals:

These purchases signal strong confidence in the company's future prospects.

Ownership Reshuffling

Concurrent with these acquisitions, two other significant stakeholders decided to reduce their positions in the company:

The consistency in price across all transactions suggests a mutually agreed valuation among the involved parties.

Market Response

The market's reaction to these bulk deals has been overwhelmingly positive, as evidenced by the sharp rise in Balaxi Pharmaceuticals' stock price. A 22% increase over two trading sessions underscores the heightened investor interest and potential optimism surrounding the company's future.

Implications for Balaxi Pharmaceuticals

While the immediate impact is reflected in the stock's performance, the long-term implications of this ownership reshuffle remain to be seen. The entry of new institutional investors could potentially bring fresh perspectives and strategies to Balaxi Pharmaceuticals' operations and growth plans.

Investors and market analysts will be keenly watching how these changes in ownership might influence the company's direction and performance in the coming months.

Note: This article is based on the latest available information and does not constitute investment advice. Investors should perform their own due diligence before making any investment decisions.